Chapter 6: Blood pressure management in children with CKD ND  by unknown
Chapter 6: Blood pressure management in children
with CKD ND
Kidney International Supplements (2012) 2, 372–376; doi:10.1038/kisup.2012.56
INTRODUCTION
This chapter addresses the management of BP in children
(defined as 18 years or younger, although chronological age
does not necessarily parallel biological or social development).
Children with non-dialysis-dependent CKD (CKD ND) differ
from adults in the etiologies of CKD, definition of hyperten-
sion, and CKD associated co-morbidities. As cardiovascular
end points such as myocardial infarction, stroke, or cardio-
vascular death are rare, effects of high BP and its treatment on
kidney outcomes (e.g., lowering of GFR, initiation of dialysis,
or transplantation) and target-organ damage are relevant end
points in studies of children with CKD, although in the
longer-term, CVD has a more important role.
Elevated BP and high BP are common in children with
CKD, but RCTs of various treatment agents or targets are
scarce. Observational studies and registry data311–315 demon-
strate that more than half of children with CKD have high BP
based upon a casual BP reading. Observational data also
suggest that hypertensive children with CKD progress to
kidney failure significantly faster than normotensive children
with CKD.313 In studies of young adults with kidney failure
whose kidney disease began in childhood, the risk of
cardiovascular death is extremely high.316,317 Sudden cardiac
death is the main cause of cardiac death in these
individuals.318
In light of the high prevalence and substantial morbidity
associated with elevated BP in children with CKD, we
systematically reviewed the existing literature and previously
published guideline statements regarding the management of
elevated BP in this vulnerable population. As RCTs are
considered to provide the strongest evidence for CPGs, we
reviewed RCTs with kidney and cardiovascular outcomes in
which children with CKD was the study population. We
supplemented this limited RCT evidence with information
obtained from case series, cohort studies, and previous
guideline statements on BP in healthy children and children
with CKD. We further described the evidence base in detail in
the narrative following each recommendation statement.
The strict evidence-based approach of formulating
recommendations may have resulted in statements that do
not include some commonly accepted treatment practices in
children. The rationale for this approach is that we do not
wish to provide guideline recommendations and discourage
research in areas where evidence is weak. The research
recommendations listed at the end of the chapter illustrate
areas where more evidence is needed.
BACKGROUND
Definitions. For this Guideline, the age range for children
is defined as from birth through 18 years. The preferred
method of BP measurement in children is auscultation, and
reference tables for BP percentiles for age, sex, and height can
be accessed at the National Heart, Lung, and Blood Institute’s
Fourth Report on the Diagnosis, Evaluation, and Treatment of
High BP in Children and Adolescents at http://www.nhlbi.
nih.gov/health/prof/heart/hbp/hbp_ped.pdf.319
Throughout this guideline when we refer to thresholds
or targets for BP therapy, we are referring to manual,
auscultatory measurements of both systolic and diastolic
BP unless otherwise specified. Correct BP measurement
requires a cuff that is appropriate to the size of the child’s
upper arm and elevated BP must be confirmed on repeated
visits. In deciding on treatment, unless severe hypertension
is present, an individual’s BP level should be determined as
an average of multiple BP measurements taken over weeks
to months.319 Current recommendations suggest that
measurements obtained by oscillometric devices that
exceed the 90th percentile for age, sex, and height should be
repeated by auscultation.319 Detailed descriptions of
appropriate BP measurement techniques in children and
the strengths and limitations of various BP measure-
ment methods in children with CKD have been detailed
previously in the KDOQI Clinical Practice Guidelines
on Hypertension and Antihypertensive Agents in Chronic
Kidney Disease, Guideline 13: Special Considerations in
Children.1
Although there is insufficient trial evidence to recommend
the use of ABPM in this Guideline, by virtue of frequent
measurement and recording, ABPM allows the practitioner
to compute the mean BP during the day, night, and over 24
hours, as well as to assess the time in which BP exceeds the
upper limit of the normal range (i.e., the BP load). A number
of reviews and guidelines suggest that in children with CKD,
ABPM is a particularly useful tool to assess BP patterns.320–322
In children, ABPM can be particularly useful, as a significant
number of patients have masked hypertension and would not
be recognized as having hypertension based on the outpatient
measurements only. A few studies using ABPM in patients
with CKD suggest that it may give a better measure of overall
BP and better indicate risk for kidney disease progression
than office BP measurement.12,77,323 In fact, the only large
RCT of BP control in children with CKD used ABPM as the
method for BP assessment.14 Further research may elucidate
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that future guidelines for therapy should be based on ABPM,
rather than office based measures that are commonly used
today. We have not recommended ABPM targets in this
Guideline as ABPM is currently expensive and not readily
available as routine clinical care in many settings.
6.1: We recommend that in children with CKD ND, BP-
lowering treatment is started when BP is consistently
above the 90th percentile for age, sex, and height. (1C)
RATIONALE
CVD has long been recognized as a substantial cause of late
morbidity and mortality in individuals with onset of CKD
during childhood.324 The majority of children with CKD are
hypertensive,312 and a substantial proportion show evidence
of target-organ damage associated with both masked and
confirmed hypertension in a dose–dependent fashion.325
However, few RCTs directly comparing thresholds for
initiation of BP treatment (vs. no treatment) or targets of
BP treatment to prevent or reverse target-organ damage have
ever been performed in children with CKD.
Observational studies of healthy children suggest that
persistent elevations in BP are associated with significant late
sequelae. In cross-sectional studies, elevated BP is associated
with evidence of target-organ damage, including left
ventricular hypertrophy and increased carotid intimal–medial
thickness.326 In longitudinal analysis from the Bogalusa Heart
Study, high systolic or diastolic BP was associated with an
increased risk of developing kidney failure during long-term
follow-up,327 and high childhood BP was an independent
predictor of increased ankle–brachial pulse wave velocity in
young adults.328 Persistently elevated BP in the young has
been associated with decreased measures of carotid artery
elasticity.329
In healthy children, in the absence of long-term data linking
specific BP levels with adverse cardiovascular or kidney events,
hypertension is defined on the basis of a population-based
distribution. Specifically, hypertension is defined as average
systolic BP or diastolic BP that is greater than or equal to the
95th percentile for sex, age, and height on three or more
occasions.319 In healthy children, the goal of anti-hypertensive
treatment is reduction of the BP to below the 95th percentile,
unless concurrent conditions are present. CKD is considered
such a concurrent condition. In children with CKD, according
to the Fourth Report on the Diagnosis, Evaluation, and Treat-
ment of High BP in Children and Adolescents, the BP should be
lowered to below the 90th percentile (http://www.nhlbi.nih.
gov/health/prof/heart/hbp/hbp_ped.pdf).319 The rationale for
this approach is similar to the recommended treatment of
hypertension in adults with additional cardiovascular risk
factors or co-morbid conditions.
A number of expert panels have reviewed the existing
literature and made similar recommendations. The National
High Blood Pressure Education Program Working Group on
High BP in Children and Adolescents has recommended
initiating pharmacologic therapy for BP above the 90th
percentile if a compelling indication such as CKD is
present.319 In 2004, the NKF KDOQI Clinical Practice
Guidelines on Hypertension and Antihypertensive Agents in
Chronic Kidney Disease1 recommended that the target BP in
children with CKD should be lower than the 90th percentile
for normal values adjusted for age, sex, and height oro130/
80mmHg, whichever is lower. Similarly, the Cardiovascular
Risk Reduction in High-Risk Pediatric Patients report330
listed children with CKD or kidney failure as a pediatric
population at high risk for CVD, for which a target BP below
the 90th percentile for age, sex, and height is suggested.
According to that consensus statement, CKD is considered a
coronary heart disease equivalent for which the treatment
recommendations are similar to those in secondary preven-
tion guidelines for adults with established coronary disease.
Among children with CKD, observational data have
shown that those with hypertension (i.e., BP above the 95th
percentile) have a more rapid decline in estimated GFR than
those without hypertension.313,331 In a study by the European
Study Group of Nutritional Treatment of Chronic Renal
Failure in Childhood, children with a systolic BP
4120mmHg had a significantly faster decline in GFR.332
In children who have received a kidney transplant, hyperten-
sion is a strong predictor of accelerated GFR decline333 and
graft loss.334,335 Preliminary data from the ongoing observa-
tional Chronic Kidney Disease in Children (CKiD) study
show that, among 425 children with repeated measures of
GFR, having systolic BP above the 90th percentile for age, sex,
and height is associated with faster progression of CKD as
compared with lower BP.336 In this cohort, the annualized
percent change in GFR among those with systolic BP above
the 90th percentile was 7.5ml/min/1.73 m2 (95% CI
16.6–0.1), compared to 3.8 (95% CI 11.8–3.8) in those
with systolic BP between the 50th and 90th percentiles and
2.5 (95% CI 8.9–3.9) in those with systolic BP below the
50th percentile. In the ESCAPE trial (described in detail in the
next section), the kidney survival rate was 66% during
follow-up among those with systolic BP below the 90th
percentile but only 41% among those with systolic BP above
the 90th percentile (P¼ 0.0002). In ESCAPE, a diastolic BP
below the 90th percentile was associated with a kidney
survival rate of 67%, compared to 28% among those
with diastolic BP above the 90th percentile (Po0.0001)
(F. Schaefer and E. Wuhl, personal communication). On the
basis of the RCT evidence, observational data, and other
guidelines, the Work Group graded this recommendation as
1C. The quality of evidence was graded as C because the RCT
evidence is limited to inferred evidence from one trial.
6.2: We suggest that in children with CKD ND (parti-
cularly those with proteinuria), BP is lowered to
consistently achieve systolic and diastolic readings
less than or equal to the 50th percentile for age, sex,
and height, unless achieving these targets is limited
by signs or symptoms of hypotension. (2D)
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RATIONALE
The evidence for this recommendation comes largely from the
ESCAPE trial,14 which showed a benefit in slowing CKD
progression by targeting 24-hour MAP by ABPM to less than
the 50th percentile for age, height and sex. Secondary analysis
of the data suggested the effect was stronger in proteinuric
children with CKD. (See Supplementary Tables 63–64 online).
Based largely on the ESCAPE results, the European Society of
Hypertension guidelines recently recommended that in
children with CKD, BP targets should be below the 50th
percentile in the presence of proteinuria and below the 75th
percentile in the absence of proteinuria.337 In the European
Society of Hypertension guidelines, the rationale for choosing
the 75th percentile as a threshold in children with CKD
without proteinuria is based on a re-analysis of ESCAPE
results, examining kidney outcomes according to achieved
24-hour mean BP level. Since the 75th percentile was not an
original targeted intervention in the ESCAPE trial, and the
trial was not powered to detect differences by levels of
proteinuria in recruited subjects, we have not made a separate
specific recommendation distinguishing between the presence
and absence of proteinuria for target BP levels for children
with CKD, but this is an important area for future study.
Our guideline includes a statement of caution in
aggressively pursuing low BP targets in children with CKD.
We recognize that children are particularly susceptible to
intercurrent illnesses, gastroenteritis and dehydration, and
aggressive use of BP lowering medications in polyuric and
dehydrated patients can lead to hypotension and alterations
in renal perfusion. Clinicians who prescribe anti-hypertensive
medications, particularly ACE-Is and ARBs in children need
to be aware of the risk of drug toxicity in children susceptible
to intravascular dehydration. Clinicians should consider
discontinuing the drugs in the presence of acute diarrhea.338
Additionally we recognize that reaching a target of less than
the 50th percentile BP may be quite difficult in some children
with CKD. The risks of polypharmacy have to be weighed
against the potential benefits of achieving lowered BP.
In the ESCAPE trial,14 468 hypertensive children with a
24-hour MAP above the 95th percentile for age, sex, and
height, and a GFR (based on the Schwartz formula) of
15–80ml/min/1.73 m2, received ramipril at a fixed dose of
6mg/m2/day and were randomized to target a 24-hour MAP,
measured by means of ABPM, of either between the 50th and
90th percentile or below the 50th percentile. Additional anti-
hypertensive agents, except for other antagonists of the
RAAS, were added at the discretion of the local provider to
achieve the target BP.
In this study—the largest prospective RCT of BP therapy
in children with CKD to date—fixed-dose ramipril and a
lower therapeutic BP target (MAP below the 50th percentile
for age, sex, and height by ABPM delayed the progression to
kidney failure. There were no differences in the frequency or
types of adverse events between the intensified and conven-
tional BP target arms in the trial. In subsequent stratified
analyses, the effects were more pronounced in children with
glomerulopathy and kidney hypodysplasia or dysplasia. There
was no evidence of improved outcomes in individuals with
hereditary nephropathies or other congenital causes of kidney
disease other than aplasia or dysplasia, although there were
relatively few individuals in these subgroups. Additionally, in
stratified analyses, the efficacy of the intensified BP control
intervention was most marked in children with a urine PCR
of 4150mg/g (415mg/mmol) (see supplement of Wuhl
et al.14).
Data presented at the American Society of Nephrology
2010 annual meeting from the observational CKiD study336
also shows slower progression of decline in kidney function
in individuals with auscultatory manual BP below the 50th
percentile for age, sex, and height as compared to individuals
with BP between the 50th and 90th percentile and those with
BP above the 90th percentile. BP in this study is measured
according to a standard protocol at annual study visits with
an aneroid device.
BP targets in children with CKD should be individualized on
the basis of susceptibility to hypotension. Many causes of
childhood CKD include diagnoses associated with salt and water
losses in the urine. As such, the risk of hypotension associated
with aggressive BP control should temper the ramping-up of
BP-lowering medication to reach a low BP target.
6.3: We suggest that an ARB or ACE-I be used in children
with CKD ND in whom treatment with BP-lowering
drugs is indicated, irrespective of the level of
proteinuria. (2D)
RATIONALE
This recommendation is based on published experience with
these agents in children with hypertension, showing the drugs
to be safe and effective in lowering BP and to confer a benefit
for slowing CKD and reducing urine protein levels in adults
with CKD. However in teenage girls, pregnancy testing and
the use of birth control prior to and during ACE-I/ARB
therapy need to be considered. Additionally, as mentioned
above, discontinuing these agents during episodes of
diarrheal illness and dehydration should be considered.338
ACE-Is or ARBs should be the preferred choice in treating
proteinuric CKD (see Chapters 3 and 4). Multiple studies in
adults with CKD have shown renoprotection with the use of
ACE-Is or ARBs. RAAS antagonists preserve kidney function
not only by lowering BP but also by means of anti-proteinuric,
anti-fibrotic, and anti-inflammatory properties. In the ESCAPE
trial described above, on the basis of previous research in
adults, the children in both arms of the intervention received a
fixed, maximum dose of the ACE-I ramipril.323 Further BP
lowering was achieved through the addition of other medica-
tions at the discretion of the local provider.
Others have recommended ACE-Is or ARBs as first-line
agents in treating children with CKD and high BP,339
particularly in those with proteinuria.340 The recently
released European Society of Hypertension guidelines337
assert that ‘it is reasonable to recommend agents blocking
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the renin–angiotensin system as first choice in proteinuric,
and also in non-proteinuric patients with CKD.’ How-
ever, limited direct evidence from clinical trials is available
with which to assess the efficacy of RAAS in children with
CKD. In healthy children with hypertension, a number
of clinical trials have examined the safety and efficacy of
ACE-Is.341–345 Small, uncontrolled studies have shown stable
kidney function in children with CKD treated with ACE-Is
or ARBs.346–348 Kidney dysfunction that is hemodynamic in
origin has been more commonly associated with the use of
ACE-Is and ARBs than with other anti-hypertensive agents.
Additionally, since elevations in serum potassium levels have
also been observed, counselling about potassium intake and
addition of thiazide or loop diuretics are sometimes
advised.339
Although analysis of registry data from the ItalKid
Project database failed to show clear evidence of ACE-I
efficacy in slowing the progression of CKD,311 other
observational evidence shows that ACE-Is are associated with
lower urine protein levels349 and that BP control in childhood
CKD is superior with anti-hypertensive regimens containing
an ACE-I or ARB.312 In a small trial, an ARB was more
effective at lowering urine protein levels than a calcium-
channel blocker.350 The only study to date that has compared
ACE-Is and ARBs in children found that urine protein levels
were similarly reduced with the ACE-I enalapril and the ARB
losartan.351
As in adults, ARBs may be more tolerable than ACE-Is in
children, with fewer adverse events such as cough, angio-
neurotic edema, and hyperkalemia—but this has not been
systematically studied in large trials. Combination therapy
with ACE-Is and ARBs may be used for additive anti-
proteinuric and renoprotective effects, but this approach has
rarely been studied in children. Small randomized trials of
combinations of ACE-Is and ARBs in children with CKD
demonstrate significant reductions in urine protein levels as
compared to the use of only one of the drug classes.335,352
However, further study of long-term outcomes and safety
data are necessary.
Use of ACE-Is and ARBs should be individualized on the
basis of susceptibility to hypotension and of the risk of
pregnancy in young women of child-bearing age. ACE-Is and
ARBs are labelled by the US FDA as pregnancy category C for
the first 3 months of pregnancy and category D for the last
6 months (the second and third trimesters). Pregnancy
category C means that a risk may exist but its magnitude is
unknown because of a lack of trustworthy studies in pregnant
women, and animal studies either have shown risk in
pregnancy or have not been performed. Pregnancy category
D means that there have been studies in pregnant women
showing that the drug is associated with some risk for the
fetus, but the benefit of the drug may still outweigh that risk
for some patients.84,85
Monitoring for hyperkalemia may be considered in high-
risk children as kidney function declines. In the ESCAPE
trial,14 individuals with CKD receiving a high-dose ACE-I
had an increase in mean (±standard deviation [SD]) serum
potassium levels from 4.31±0.52mmol/l to 4.71±
0.57mmol/l. The upper limit of the normal range for
children (5.6mmol/l) was exceeded in 3.3% of tests. In all
but 5 patients, medical management through adjustment of
diet, addition of a diuretic, or prescription of potassium-
exchange resins resulted in persistent normalization of serum
potassium levels while the child remained on ACE-I therapy.
ACE-Is and ARBs have similar hemodynamic effects in the
kidney which leads to decrease in GFR. It has been stated that
increases of the SCr level by up to 30% should be expected
and tolerated after initiating therapy with ACE-Is or ARBs in
adults with chronic kidney failure, but children have not been
prospectively studied in this regard.88
Few direct comparisons of classes of anti-hypertensive
agents have been performed in children with CKD. Extensive
reviews of different drugs and classes of anti-hypertensive
agents in children with CKD have recently been pub-
lished.337,339 There is no clear evidence that one second-line
BP agent is superior to the another in children. In the
ESCAPE trial,14 calcium-channel blockers were used as first-
choice anti-hypertensive co-medication (in 38% of patients),
followed by diuretics (in 36%) and beta-blockers (in 26%),
without differences between the randomization groups.
Other guidelines suggest diuretics or calcium-channel block-
ers as the most suitable second-line agents.353
LIMITATIONS
In children with CKD, there is a dearth of RCTs; in fact, the
recommendations in this chapter are largely based on a single
trial, ESCAPE, which limits the quality of the evidence and
the strength of the recommendations. The ESCAPE trial was
performed in a predominantly Caucasian population. There-
fore, the generalization of these findings to other populations
is uncertain.
RESEARCH RECOMMENDATIONS
K Further RCTs are needed to replicate the findings from
ESCAPE and to examine the safety and efficacy of
intensified BP control on slowing CKD progression and
incidence of CVD in children with CKD.
K Studies addressing BP targets and comparing home BP
monitoring via oscillometric devices, ABPM, and clinic-
based BP monitoring are needed, as are robust ABPM
reference measures in populations of various races and
ethnicities.
K Long-term observational studies of the onset of target-
organ damage in children with CKD are necessary to
obtain evidence on which to base thresholds for BP
treatment and targets rather than relying on population-
based percentiles. Large, long-term randomized trials
addressing targets and comparing various agents to
prevent target-organ damage are also necessary to
improve knowledge of the advantages and disadvantages
of specific doses and classes of anti-hypertensive agents in
this population.
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